Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study

Arthritis and Rheumatism

Volumn 64, Issue 11, 2012, Pages 3666-3676

  McBride, Jacqueline M ^a   Jiang, Jenny ^a   Abbas, Alexander R ^a   Morimoto, Alyssa ^a   Li, Jing ^a   MacIuca, Romeo ^a   Townsend, Michael ^a   Wallace, Daniel J ^b   Kennedy, William P ^a   Drappa, Jorn ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; AUTOANTIBODY; DOUBLE STRANDED DNA; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RONTALIZUMAB; STEROID;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; DISEASE MARKER; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLACEBOS; SEVERITY OF ILLNESS INDEX; TRANSCRIPTOME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868144947     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34632     Document Type: Article

References (37)

1. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL,. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8.
2. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK,. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-503.
3. Ytterberg SR, Schnitzer TJ,. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25: 401-6.
4. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J,. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 1982; 216: 429-31.
5. Graham RR, Hom G, Ortmann W, Behrens TW,. Review of recent genome-wide association scans in lupus. J Intern Med 2009; 265: 680-8.
6. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK,. Association of the IRF5 risk haplotype with high serum interferon-α activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58: 2481-7.
7. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY,. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177-86.
8. Hua J, Kirou K, Lee C, Crow MK,. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-16.
9. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23.
10. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK,. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492-502.
11. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5.
12. Delgado-Vega AM, Alarcon-Riquelme ME, Kozyrev SV,. Genetic associations in type I interferon related pathways with autoimmunity. Arthritis Res Ther 2010; 12 Suppl 1: S2.
13. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550-5.
14. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007; 104: 6758-63.
15. Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr,. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64: 1692-7.
16. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, FitzGerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951-62.
17. Ronnblom LE, Alm GV, Oberg KE,. Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178-83.
18. Ronnblom LE, Alm GV, Oberg K,. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-α treatment. Acta Oncol 1991; 30: 537-40.
19. Ronnblom LE, Alm GV, Oberg KE,. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207-10.
20. Niewold TB, Swedler WI,. Systemic lupus erythematosus arising during interferon-α therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178-81.
21. Gota C, Calabrese L,. Induction of clinical autoimmune disease by therapeutic interferon-α. Autoimmunity 2003; 36: 511-8.
22. Ioannou Y, Isenberg DA,. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy [review]. Arthritis Rheum 2000; 43: 1431-42.
23. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
24. Hochberg Y, Benjamini Y,. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811-8.
25. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OCSELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-8.
26. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491.
27. Ronnblom L, Alm GV,. A pivotal role for the natural interferon α-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001; 194: F59-63.
28. Ronnblom L, Elkon KB,. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6: 339-47.
29. Banchereau J, Pascual V,. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25: 383-92.
30. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6: 722-9.
31. Chen HM, Tanaka N, Mitani Y, Oda E, Nozawa H, Chen JZ, et al. Critical role for constitutive type I interferon signaling in the prevention of cellular transformation. Cancer Sci 2009; 100: 449-56.
32. Picaud S, Bardot B, De Maeyer E, Seif I,. Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 2002; 22: 457-62.
33. McCarty MF, Bielenberg D, Donawho C, Bucana CD, Fidler IJ,. Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 2002; 19: 609-15.
34. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60: 3098-107.
35. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
36. Pestka S, Krause CD, Walter MR,. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 32.
37. Crow MK, Kirou KA,. Interferon-induced versus chemokine transcripts as lupus biomarkers. Arthritis Res Ther 2008; 10: 126.